Cadila Gets FDA Nod for Arthritis Drug (India)
This article was originally published in PharmAsia News
Executive Summary
Major Indian pharmaceutical manufacturer Zydus Cadila Healthcare announced on Sept. 25 that it has received approval from the U.S. FDA for a new drug to treat rheumatoid arthritis. The FDA approval is for a 200mg dose of hydrochloroquine sulfate. The drug is one of a class of arthritis-fighting treatments known as disease modifying anti-rheumatic drugs (DMARD). DMARDs are designed to reduce the pain, inflammation, and joint damage caused by the disease for a period of several weeks or several months depending on the treatment. (Click here for more